News & Insights

Bio Spectrum India

  • BSI- Oct 2017: Vipragen is cited in page 23 of the journal.

Though India makes up 16% of the world's population and 20% of the world's disease burden, less than 1.4% of global clinical trials are carried out in the country. Of 236,329 ongoing global clinical studies, only 3,016 studies are being done in India, placing it way behind the USA, Europe, Japan, China, Malaysia and Taiwan. The low number ranks India in the fifth position in Asia. - Dr Chaitra Harsha, Managing Director, Vipragen Biosciences.

Article in Pressreader

  • Article in the Pressreader journal.

In a short time since its inception, Vipragen has achieved global accreditations by CPCSA, AAALAC and is on the verge of achieving GLP accreditation. Vipragen was also one among the 11 biotech start-ups to get prestigious recognition at Elevate 100, a Government of Karnataka initiative to fund innovative start-ups in the state.

Article in Israel-India Business

  • Vipragen on Israel India Company Profile.

VIPRAGEN BIOSCIENCES is an integrated Pre-Clinical technology provider Biotech company based at Mysore. We partner and collaborate with biotech, pharma, research or new ventures providing research capabilities in Preclinical Biology, Microbiology, Molecular biology, Cell culture, Pharmacology, Toxicology, ADME / DMPK, drug discovery research and new product development areas. Vipragen was conceptualized by a team of scientists with vast experience and expertise in various companies in the areas of drug discovery and biotechnology research. With the state of the art in vitro biology and laboratory animal facility accredited by CPCSEA, AAALAC and Drug testing certification.

Nikkei Asian Review

  • Indian biotech boom triggers surge in research startups- Nikkei Asian. (or)

Veena Rao, CEO of Vipragen, a startup founded in 2012 in Bangalore, said the drug-discovery environment has seen a surge of small companies. "Biotech companies need a strategic preclinical partner for performing discovery-driven, preclinical testing," she said. "Also, the ability to offer cost-effective and quality service is one of the contributing factors in starting a [contract research] service company."

Vipragen, which had revenues of 32 million rupees in the fiscal year ended March 2017, provides early-stage screening for safety and efficacy of drugs and chemicals before human use.

Article in The Economic Times

  • Karnataka picks up 100 most innovative startups, to give Rs 35 Cr in funding - The Economic Times.

The ELEVATE 100 roadshow has traversed the length and breadth of Karnataka in a rigorous hunt to pick the 100 most innovative start-ups and help them turn their ideas into successful businesses. The short-listed startups will have access to the government’s start-up fund besides access to government VC funds, pilots, private VC funds, world class accelerators and mentors, the IT department said in a press release.

Chronical Pharmabiz

  • Article in Chronical Pharmabiz

Apart from generation of huge amount of intellectual properties, Vipragen will provide its technical and pre-clinical expertise and work exclusively with the American company for the development of the drug and clinical treatment strategies.